Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-08-2017 | Original Paper

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders

Authors: Viktoria Johansson, Joel Jakobsson, Rebecca G. Fortgang, Henrik Zetterberg, Kaj Blennow, Tyrone D. Cannon, Christina M. Hultman, Lennart Wetterberg, Mikael Landén

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 5/2017

Abstract

Schizophrenia and bipolar disorder are debilitating psychiatric disorders with partially shared symptomatology including psychotic symptoms and cognitive impairment. Aberrant levels of microglia and neurodegenerative cerebrospinal fluid (CSF) markers have previously been found in schizophrenia and bipolar disorder. We aimed to analyze familial and environmental influences on these CSF markers and their relation to psychiatric symptoms and cognitive ability. CSF was collected from 17 complete twin pairs, nine monozygotic and eight dizygotic, and from one twin sibling. Two pairs were concordant for schizophrenia, and 11 pairs discordant for schizophrenia, schizoaffective disorder or bipolar disorder, and four pairs were not affected by psychotic disorders. Markers of microglia activation [monocyte chemoattractant protein-1 (MCP-1), chitinase 3-like protein 1 (YKL-40), and soluble cluster of differentiation 14 (sCD14)], markers of β-amyloid metabolism (AβX-38, AβX-40, AβX-42 and Aβ1-42), soluble amyloid precursor proteins (sAPP-α and sAPP-β), total tau (T-tau), phosphorylated tau (P-tau), and CSF/serum albumin ratio were measured in CSF using immunoassays. Heritability of the CSF markers was estimated, and associations to psychiatric and cognitive measurements were analyzed. Heritability estimates of the microglia markers were moderate, whereas several neurodegenerative markers showed high heritability. In contrast, AβX-42, Aβ1-42, P-tau and CSF/serum albumin ratio were influenced by dominant genetic variation. Higher sCD14 levels were found in twins with schizophrenia or bipolar disorder compared to their not affected co-twins, and higher sCD14-levels were associated with psychotic symptoms. The study provides support for a significant role of sCD14 in psychotic disorders and a possible role of microglia activation in psychosis.

Available only for authorised users

Merikangas KR et al (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3):241–251CrossRefPubMedPubMedCentral

McGrath J et al (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76CrossRefPubMed

Lichtenstein P et al (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373(9659):234–239CrossRefPubMed

Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381(9875):1371–1379CrossRefPubMedCentral

Benros ME et al (2011) Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 168(12):1303–1310CrossRefPubMed

Benros ME et al (2013) Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 70(8):812–820CrossRefPubMed

Johansson V et al (2014) Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort. Mult Scler 20(14):1881–1891CrossRefPubMed

Mors O, Mortensen PB, Ewald H (1999) A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophr Res 40(1):67–74CrossRefPubMed

Bergink V, Gibney SM, Drexhage HA (2014) Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 75(4):324–331CrossRefPubMed

10.

Horvath S, Mirnics K (2014) Immune system disturbances in schizophrenia. Biol Psychiatry 75(4):316–323CrossRefPubMed

11.

Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155(1–3):101–108CrossRefPubMed

12.

Munkholm K et al (2013) Cytokines in bipolar disorder versus healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 47(9):1119–1133CrossRefPubMed

13.

Miller BJ et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671CrossRefPubMedPubMedCentral

14.

Dargel AA et al (2015) C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry 76(2):142–150CrossRefPubMed

15.

Smith RS (1992) A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 39(3):248–257CrossRefPubMed

16.

Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35(4):298–306CrossRefPubMed

17.

Janova H et al (2016) CD14 is a key organizer of microglial responses to CNS infection and injury. Glia 64(4):635–649CrossRefPubMed

18.

Severance EG et al (2013) Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 148(1–3):130–137CrossRefPubMedPubMedCentral

19.

Jakobsson J et al (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 40(4):250–258CrossRefPubMedPubMedCentral

20.

Padmos RC et al (2008) A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 65(4):395–407CrossRefPubMed

21.

Maier B et al (2005) Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma 22(7):822–835CrossRefPubMed

22.

Meier MH et al (2014) Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. Am J Psychiatry 171(1):91–101CrossRefPubMedPubMedCentral

23.

Xu G et al (2012) Neuropsychological performance in bipolar I, bipolar II and unipolar depression patients: a longitudinal, naturalistic study. J Affect Disord 136(3):328–339CrossRefPubMed

24.

Palsson E et al (2013) Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. BMC Psychiatry 13:165CrossRefPubMedPubMedCentral

25.

Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368(9533):387–403CrossRefPubMed

26.

Blennow K et al (2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36:297–309CrossRefPubMed

27.

Albertini V et al (2012) Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer’s disease and schizophrenia. Electrophoresis 33(24):3738–3744CrossRefPubMed

28.

Dwork AJ et al (1998) Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 155(11):1536–1543CrossRefPubMed

29.

Chung JK et al (2016) Beta-amyloid burden is not associated with cognitive impairment in schizophrenia: a systematic review. Am J Geriatr Psychiatry 24(10):923–939CrossRefPubMed

30.

Jakobsson J et al (2013) Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 38(4):664–672CrossRefPubMed

31.

Piccinni A et al (2012) Plasma beta-amyloid peptides levels: a pilot study in bipolar depressed patients. J Affect Disord 138(1–2):160–164CrossRefPubMed

32.

Johansson V et al (2012) Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophrenia or bipolar disorder and in healthy controls. PLoS ONE 7(9):e45994CrossRefPubMedPubMedCentral

33.

Mobarrez F et al (2013) Microparticles and microscopic structures in three fractions of fresh cerebrospinal fluid in schizophrenia: case report of twins. Schizophr Res 143(1):192–197CrossRefPubMed

34.

Spitzer RL et al (1992) The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49(8):624–629CrossRefPubMed

35.

First MB et al (1997) Structured clinical interview for DSM-IV axis II personality disorders (SCID-II). American Psychiatric Press Inc., Washington, DC

36.

Raine A (1991) The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 17(4):555–564CrossRefPubMed

37.

Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51(6):768–774CrossRefPubMed

38.

Zuckerman M, Link K (1968) Construct validity for the sensation-seeking scale. J Consult Clin Psychol 32(4):420–426CrossRefPubMed

39.

Akiskal HS et al (2005) TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament. J Affect Disord 85(1–2):45–52CrossRefPubMed

40.

Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City

41.

Andreasen NC (1984) The scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City

42.

Hannelius U et al (2007) Large-scale zygosity testing using single nucleotide polymorphisms. Twin Res Hum Genet 10(4):604–625CrossRefPubMed

43.

Akaike H (1987) Factor analysis and AIC. Psychometrika 52(3):317–332CrossRef

44.

Kline RB (2011) Principles and practice of structural equation modeling, 3rd edn. The Guilford Press, New York

45.

Neale M et al (2003) Mx: Statistical modeling. Department of Psychiatry, Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, Richmond

46.

Jakobsson J et al (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 40(2):140183

47.

Brodin P et al (2015) Variation in the human immune system is largely driven by non-heritable influences. Cell 160(1–2):37–47CrossRefPubMedPubMedCentral

48.

LeVan TD et al (2001) A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 167(10):5838–5844CrossRefPubMed

49.

Baldini M et al (1999) A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 20(5):976–983CrossRefPubMed

50.

de la Fontaine L et al (2006) Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Res 144(1):39–47CrossRefPubMed

51.

Haziot A et al (1988) The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 141(2):547–552PubMed

52.

Bazil V et al (1989) Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol 26(7):657–662CrossRefPubMed

53.

Olsson B et al (2013) Microglial markers are elevated in the prodromal phase of Alzheimer’s disease and vascular dementia. J Alzheimers Dis 33(1):45–53PubMed

54.

Yin GN et al (2009) Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 87(11):2578–2590CrossRefPubMed

55.

Bernstein HG et al (2016) Morphometric analysis of the cerebral expression of ATP-binding cassette transporter protein ABCB1 in chronic schizophrenia: Circumscribed deficits in the habenula. Schizophr Res. doi:10.1016/j.schres.2016.02.036

56.

Zetterberg H et al (2014) Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res 217(3):143–146CrossRefPubMed

57.

Bechter K et al (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood–CSF barrier dysfunction. J Psychiatr Res 44(5):321–330CrossRefPubMed

58.

Muller N, Ackenheil M (1995) Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 14(3):223–228CrossRefPubMed

59.

Prince JA et al (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62(11):2116–2118CrossRefPubMed

60.

Lautner R et al (2014) Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71(10):1183–1191CrossRefPubMed

61.

Gatt JM et al (2015) Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res 60:1–13CrossRefPubMed

62.

Gonzalez-Castro TB et al (2015) No association between ApoE and schizophrenia: evidence of systematic review and updated meta-analysis. Schizophr Res 169(1–3):355–368CrossRefPubMed

63.

Sutin AR et al (2012) Impulsivity-related traits are associated with higher white blood cell counts. J Behav Med 35(6):616–623CrossRefPubMed

64.

Sutin AR et al (2010) High neuroticism and low conscientiousness are associated with interleukin-6. Psychol Med 40(9):1485–1493CrossRefPubMed

65.

Fortgang RG et al (2016) Multidimensional assessment of impulsivity in schizophrenia, bipolar disorder, and major depressive disorder: testing for shared endophenotypes. Psychol Med 46(7):1497–1507CrossRefPubMed

Title: Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders
Authors: Viktoria Johansson
Joel Jakobsson
Rebecca G. Fortgang
Henrik Zetterberg
Kaj Blennow
Tyrone D. Cannon
Christina M. Hultman
Lennart Wetterberg
Mikael Landén
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 5/2017
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-016-0759-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus

Abnormalities in the brain–immune system in psychotic disorders: from pathogenesis to prevention

Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders

Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia

Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort

Expressional profile of the diacylglycerol kinase eta gene DGKH